| Related LncRNAs | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ID | lncRNA Name | Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source |
| EL0012 | A130040M12Rik | cancer | N/A | N/A | N/A | expression | These results indicate that PSF is a major tumor-suppressor protein and VL30-1 RNA is a major tumor-promoter RNA in mice. | 19805375 | LncRNADisease |
| EL0083 | ARA | Cancer | microarray, qRT-PCR | MCF-7/ADR and HepG2/ADR cells | N/A | N/A | The functions of ARA were assessed by silencing this lncRNA in vitro, and ARA knockdown reduced the proliferation, induced cell death, G2/M arrest and migration defects. modulate multiple signalling pathways, including MAPK signalling pathway, metabolism pathways, cell cycle and cell adhesion-related biological pathways, and regulate cellular processes, including transcriptional processes and protein binding function. | 24184505 | |
| EL0093 | ASncmtRNAs | cancer | N/A | several tumor cell lines | down-regulated | N/A | the ASncmtRNAs are down-regulated in tumor cells regardless of tissue of origin. down-regulation of the ASncmtRNAs constitutes a vulnerability or Achilles' heel of cancer cells, suggesting that the ASncmtRNAs are promising targets for cancer therapy. | 25100722 | |
| EL0093 | ASncmtRNAs | cancer | N/A | several tumor cell lines | down-regulated | N/A | the ASncmtRNAs are down-regulated in tumor cells regardless of tissue of origin. down-regulation of the ASncmtRNAs constitutes a vulnerability or Achilles' heel of cancer cells, suggesting that the ASncmtRNAs are promising targets for cancer therapy. | 25100722 | |
| EL0246 | BOK-AS1 | cancer | N/A | N/A | N/A | expression | The expression of BOKAS was found in testis and certain cancer tissues but not in other normal adult tissues. Overexpression of BOKAS was able to inhibit Bok-induced apoptosis in HeLa cells. | 24757675 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | Interaction | RNA immunoprecipitation demonstrates that ANRIL binds to SUZ12 in vivo. Collectively, these results suggest a model in which ANRIL binds to and recruits PRC2 to repress the expression of p15(INK4B) locus. | 21151178 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | mutation | Interestingly, genome wide association studies (GWAS) identified several variants in the intergenic region encompassing ANRIL to be associated with several diseases such as coronary heart disease, intracranial aneurysm, many type of cancers and T4D | 22928560 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | expression | ANRIL is a recently discovered long non-coding RNA encoded in the chromosome 9p21 region. This locus is a hotspot for disease-associated polymorphisms, and it has been consistently associated with cardiovascular disease, and more recently with several cancers, diabetes, glaucoma, endometriosis among other conditions. | 23104877 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | expression | Another lncRNA associated with human cancers is ANRIL, a long, antisense transcript found in the INK4a/Arf locus. ANRIL is overexpressed in human leukemias and prostate cancers, and its expression leads to epigenetic silencing of the nearby tumor suppressor p15 (Yu et al., 2008; Yap et al., 2010). | 23473599 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | regulation | The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10. | 23813974 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | locus | Furthermore, genome wide association studies have identified the ANRIL gene as a risk locus for coronary disease, intracranial aneurism, type 2 diabetes and several cancers including glioma. | 24624135 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | expression | High expression of ANRIL has been found in certain cancer tissues such as melanoma and prostate cancers? | 24757675 | LncRNADisease |
| EL0289 | CDKN2B-AS1 | cancer | N/A | N/A | N/A | regulation | It has also been shown that the tumor suppressor gene p15 is silenced by its natural antisense RNA, a lncRNA ANRIL. | 24829860 | LncRNADisease |
| EL0352 | Dmrt2 | cancer | N/A | N/A | N/A | regulation | In many cancer cells TERRA is downregulated, providing a possible link to the longevity of cancer cells by telomerase-mediated lengthening of chromosomal ends. | 23660942 | LncRNADisease |
| EL0475 | EPB41L4A-AS1 | cancer | N/A | N/A | N/A | expression | Ectopic expression of TIGA1 (EPB41L4A-AS1) inhibited not only tumor cell proliferation but also anchorage-independent growth of cancer cell lines. | 16973895 | LncRNADisease |
| EL0526 | GAS5 | cancer | N/A | N/A | N/A | regulation | Pickard et al. showed that GAS5 promotes apoptosis of prostate cells after irradiation with UV, and low GAS5 expression therefore reduces the effectiveness of chemotherapeutic agents. | 24757675 | LncRNADisease |
| EL0556 | H19 | cancer | N/A | N/A | N/A | expression | The human H19 gene is frequently overexpressed in myometrium and stroma during pathological endometrial proliferative events. | 15618002 | LncRNADisease |
| EL0556 | H19 | cancer | N/A | N/A | N/A | expression | H19 expression was found in the hepatic metastases of 64 of 80 patients. High expression (higher staining grades) of H19 in the metastases was found in 43 of 80 patients. However, H19 expression status in the hepatic metastases did not correlate with either the length of time to development of metastasis or overall survival. | 16189152 | LncRNADisease |
| EL0578 | HOTAIR | cancer | N/A | N/A | N/A | epigenetics | Epigenetically silences gene expression at many loci by recruitment of LSD1/CoREST/REST and PRC2 repressive chromatin modifying complexes. Oncogene: promotes tumour metastasis. | 21256239 | LncRNADisease |
| EL0578 | HOTAIR | cancer | N/A | N/A | N/A | expression | HOTAIR is causally involved in tumor progression. It is significantly overexpressed in metastatic breast cancer. | 22045689 | LncRNADisease |
| EL0578 | HOTAIR | cancer | N/A | N/A | N/A | expression | HOTAIR overexpression is associated with poor prognosis in breast (Gupta et al. 2010), liver (Z. Yang et al. 2011), colorectal (Kogo et al. 2011), gastrointestinal (Niinuma et al. 2012), and pancreatic (Kim et al. 2012) cancers and is proposed to increase tumor invasiveness and metastasis (Gupta et al. 2010). | 23463798 | LncRNADisease |
| EL0578 | HOTAIR | cancer | N/A | N/A | N/A | expression | HOTAIR overexpression has been linked to increased invasiveness and poorer outcomes in several human cancers. | 23473599 | LncRNADisease |
| EL0578 | HOTAIR | cancer | N/A | N/A | N/A | expression | Overexpression of HOTAIR was found in breast and colon cancers and was associated with metastasis and poor prognosis. | 24757675 | LncRNADisease |
| EL0578 | HOTAIR | cancer | N/A | N/A | N/A | regulation | Forced expression of HOTAIR in epithelial cancer cells altered the localization of PRC2 on chromatin. Genome-wide studies revealed PRC2 localization more resembling occupancy in embryonic fibroblasts.? | 24829860 | LncRNADisease |
| EL0633 | KRAS1P | cancer | N/A | N/A | N/A | regulation | Similarly, KRAS and KRAS1P transcript levels were found to be positively correlated, corroborating that pseudogene functions mirror the role of their cognate genes as explained by the miRNA decoy mechanism.? | 24757675 | LncRNADisease |
| EL0660 | LINC00538 | cancer | N/A | N/A | N/A | expression | Expression profiling revealed a general and regulated expression pattern of Yiya in major tissues, and more interestingly, identified elevated mRNA levels in different cancers. | 22258142 | LncRNADisease |
| EL0853 | MALAT1 | cancer | N/A | N/A | N/A | expression | The expression of the long ncRNA MALAT1 correlates with tumor development, progression or survival in lung, liver and breast cancer. | 20711585 | LncRNADisease |
| EL0853 | MALAT1 | cancer | N/A | N/A | N/A | expression | MALAT1 is a highly conserved long ncRNA originally identified as a transcript overexpressed in many cancers. | 20864030 | LncRNADisease |
| EL0853 | MALAT1 | cancer | N/A | N/A | N/A | regulation | MALAT1 (metastasis-associated lung adenocarcinoma transcript 1),another lncRNA associated with various cancers and metastasis (Ji et al. 2003; Lin et al. 2011)锛?, is found to affect the transcriptional and post-transcriptional regulation of cytoskeletal and extracellular matrix genes. | 23463798 | LncRNADisease |
| EL0853 | MALAT1 | cancer | N/A | N/A | N/A | expression | MALAT1 is upregulated in several cancer types and its overexpression has been linked to an increase in cell proliferation and migration in lung and colorectal cancer cells. | 23660942 | LncRNADisease |
| EL0853 | MALAT1 | cancer | N/A | N/A | N/A | regulation | They found that MALAT1 did not alter alternative splicing but rather actively regulated gene expression including a set of metastasis-associated genes. Consequently, MALAT1-deficient cells were impaired in migration and formed fewer tumor nodules in mouse xenograft. Antisense oligonucleotides (ASO) that block MALAT1 prevented metastasis formation after tumor implantation. | 24757675 | LncRNADisease |
| EL0861 | MEG3 | cancer | N/A | N/A | N/A | N/A | MEG3 could represent a tumor suppressor gene located in chromosome 14q32 and its association with tumorigenesis is growing every day. | 21400503 | LncRNADisease |
| EL0861 | MEG3 | cancer | N/A | N/A | N/A | N/A | MEG3 functions as a novel lncRNA tumor suppressor. | 22393162 | LncRNADisease |
| EL0869 | MIAT | cancer | N/A | N/A | N/A | regulation | Another lncRNA serving as oncogene is retinal noncoding RNA 2 (RNCR2). | 24757675 | LncRNADisease |
| EL0878 | MIR17HG | cancer | N/A | N/A | N/A | locus | Aurora kinase A induces miR-17-92 cluster through regulation of E2F1 transcription factor. | 20300951 | LncRNADisease |
| EL0962 | NBR2 | cancer | N/A | N/A | down-regulated | interaction | involving checked cell cycling, altered apoptosis/autophagy response, and tumor development in vivo | 26999735 | |
| EL1044 | PACERR | cancer | ChIP, qPCR, RACE | primary human mammary epithelial cells and monocyte/macrophage cell lines | N/A | interaction | The lncRNA associates with p50, a repressive subunit of NF-κB, and occludes it from the COX-2 promoter, potentially facilitating interaction with activation-competent NF-κB p65/p50 dimers. | 24843008 | |
| EL1046 | PANDAR | cancer | N/A | N/A | N/A | expression | Another DNA damage-responsive, p53-induced lncRNA that lies upstream of p21, PANDA (P21 associated ncRNA DNA damage activated), is also implicated in the repression of pro-apoptotic genes, such as FAS and BIK, by acting as a decoy for the transcription factor NF-YA. In some cancer types, p53 mutations have been found that maintain the protein's ability to induce the PANDA pathway (and its antiapoptotic effects) while abolishing its ability to induce p21 and its promotion of cell-cycle arrest, thus leading to increased tumor cell survival (Hung et al. 2011). | 23463798 | LncRNADisease |
| EL1051 | PCA3 | cancer | qRT-PCR | LNCaP cell | up-regulated | N/A | PCA3 silencing modulates the expression of key cancer-related genes | 26960690 | |
| EL1097 | PTENP1 | cancer | N/A | N/A | N/A | regulation | PTENP1 pseudogene belongs to the group of competing endogenous RNAs (ceRNAs). It may act as “decoy” by protecting PTEN mRNA from binding to common miRNA and therefore allowing expression of the tumor suppressor protein.? | 24757675 | LncRNADisease |
| EL1102 | PVT1 | cancer | N/A | N/A | N/A | N/A | A single supernumerary segment encompassing all four genes(Myc gene or the region encompassing Pvt1, Ccdc26 and Gsdmc ) successfully promotes cancer; PVT1 RNA and MYC protein expression correlated in primary human tumours, and copy number of PVT1 was co-increased in more than 98% of MYC-copy-increase cancers. | 25043044 | LncRNADisease |
| EL1102 | PVT1 | cancer | N/A | N/A | N/A | expression | The PVT gene frequently amplifies with MYC in tumor cells. | 2725491 | LncRNADisease |
| EL1105 | RAB4B-EGLN2 | cancer | Genotype-phenotype correlation studies | N/A | N/A | N/A | overexpressing RERT-lncRNA upregulated EGLN2 | 23026137 | |
| EL1120 | RN7SK | cancer | N/A | N/A | N/A | Interaction | Together with the HEXIM proteins, 7SK RNA associates with and sequesters a fraction of cellular P-TEFb into a catalytically inactive complex. Active and inactive forms of P-TEFb are kept in a functional and dynamic equilibrium tightly linked to the transcriptional requirement of the cell. Importantly, cardiac hypertrophy and development of various types of human malignancies have been associated with increased P-TEFb activity, consequence of a disruption of this regulatory equilibrium. | 22377309 | LncRNADisease |
| EL1171 | RRP1B | cancer | N/A | N/A | N/A | epigenetics | RRP1B, a tumor progression and metastasis susceptibility candidate gene, is potentially a dynamic modulator of transcription and chromatin structure. | 19710015 | LncRNADisease |
| EL1263 | TARID | cancer | N/A | N/A | N/A | N/A | Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A. | 25087872 | LncRNADisease |
| EL1365 | Trp53cor1 | cancer | N/A | N/A | N/A | expression | lincRNA-p21 (named for its vicinity to the CDKN1A/p21 locus) is upregulated by p53 upon DNA damage and implicated in downstream repressive effects of the p53 pathway, particularly on genes regulating apoptosis, possibly by directing the recruitment of hnRNP-K to its genomic targets. | 23463798 | LncRNADisease |
| EL1365 | Trp53cor1 | cancer | N/A | N/A | N/A | regulation | They identified lincRNA-p21 as a direct p53 target. Furthermore, they found that lincRNA-p21 is critical in regulating many of the genes that are repressed in response to p53 activity and they found that lincRNA-p21 associates with hnRNP-K. The lincRNA-p21/hnRNP-K interaction was found to be necessary for hnRNP-K genomic localization at sites of gene repression. | 24829860 | LncRNADisease |
| EL1454 | WRAP53 | cancer | N/A | N/A | N/A | N/A | WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. | 21368886 | LncRNADisease |
| EL1454 | WRAP53 | cancer | N/A | N/A | N/A | expression | A natural antisense transcript of TP53, WRAP53, was strongly augmented by idarubicin and etoposide. | 21441950 | LncRNADisease |
| EL1459 | XIST | cancer | N/A | N/A | N/A | regulation | Dysfunction of XIST may trigger the chromatin instability and promote caner development. | 24757675 | LncRNADisease |
| EL1459 | XIST | cancer | N/A | N/A | N/A | regulation | The lncRNA Xist was found to be a potent tumor suppressor of hematologic malignancies?in vivo. | 24829860 | LncRNADisease |